A randomized, double-blind phase III study to demonstrate the clinical similarity of biosimilar SCT630 to reference adalimumab in Chinese patients with moderate to severe plaque psoriasisYu Chen, Gang Wang, Yangfeng Ding et al.|International Immunopharmacology|2022Cited by 12